Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ardea Biosciences, a biotechnology company, has announced that the US Patent and Trademark Office has issued a patent covering the composition of matter of RDEA806, the company's lead non-nucleoside reverse transcriptase inhibitor for the treatment of patients with human immunodeficiency virus and related analogs.
Subscribe to our email newsletter
RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, the company believes that RDEA806 may have important competitive advantages compared to currently available NNRTIs.
Barry Quart, president and CEO of Ardea, said: “We are very pleased with the continued expansion of our proprietary position in the non-nucleoside reverse transcriptase inhibitor area.
“This issued patent significantly enhances the value of RDEA806 and strengthens our ability to enter into future strategic alliances for its further development. We look forward to further expanding the proprietary position of RDEA806 and our other product candidates through additional future patent issuances.”